{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}]}],"title":"At least one positive sample in the ADA assay"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"At least one positive sample in the NAb assay"}],"denoms":[{"counts":[{"groupId":"OG000","value":"526"},{"groupId":"OG001","value":"521"}],"units":"Participants"}],"description":"Serum samples for immunogenicity assessment were analyzed using a bridging immunoassay to detect ADA. Positive samples in the ADA assay were further analyzed in the NAb assay using a validated, non-quantitative ligand binding assay.","groups":[{"description":"Participants with Metastatic Colorectal Cancer administered Placebo and FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)","id":"OG000","title":"Placebo/FOLFIRI"},{"description":"Participants with Metastatic Colorectal Cancer administered Aflibercept and FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)","id":"OG001","title":"Aflibercept/FOLFIRI"}],"paramType":"NUMBER","populationDescription":"Immunogenicity population included all participants who were treated and tested for immunogenicity at least once post-baseline.","reportingStatus":"POSTED","timeFrame":"Baseline, every other treatment cycle, 30 days and 90 days after the last infusion of aflibercept/placebo","title":"Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay","type":"SECONDARY","unitOfMeasure":"participants"}